title: Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy.
abstract: Current HIV-therapy recommends combination of stavudine, lamivudine and nevirapine. Stavudine and lamivudine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy by patients and therefore, there is a need to develop dosage forms that can overcome the problems of currently available dosage forms for treatment of HIV infection. The present study developed a single unit osmotic system for simultaneous and extended delivery of stavudine, lamivudine and nevirapine that can ensure patients compliance and adherence to HIV-therapy. Sandwich osmotic pump tablets (SOPTs) of stavudine, lamivudine and nevirapine in fixed dose combination were designed and evaluated for the effect of variables such as PEO (polymer), KCl (osmogen), and orifice diameter on the physicochemical characteristics and the release behavior of the drugs. A 24 h zero order release of stavudine, lamivudine and nevirapine from the formulations was observed and the release rate of the drugs was found to be affected by PEO, KCl, and orifice diameter. The in vitro release data of SOPT correlated with in vivo predictions by super - position method. The results of the study propose that a single unit osmotic system (SOPT) of stavudine, lamivudine and nevirapine is beneficial to overcome the disadvantages of currently available dosage forms for effective control of HIV infection.
authors.affiliation: Research Laboratory, Department of Pharmaceutics, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode-637 205, Namakkal Dist., Tamilnadu, India. priyanarayan97@gmail.com.
authors.forename: M Ranga
authors.initials: MR
authors.lastname: Priya
authors.forename: N N
authors.initials: NN
authors.lastname: Rajendran
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D065546:Drug Liberation; D004355:Drug Stability; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D019829:Nevirapine / Q000008:administration & dosage*; D009995:Osmosis; D011092:Polyethylene Glycols / Q000737:chemistry; D018119:Stavudine / Q000008:administration & dosage*; D013607:Tablets
chemical_list: D019380:Anti-HIV Agents; D004337:Drug Carriers; D013607:Tablets; D019259:Lamivudine; D011092:Polyethylene Glycols; D019829:Nevirapine; D018119:Stavudine